2020 年 46 巻 12 号 p. 681-691
We have established a collaboration system between community pharmacies and our hospital using the sharing tools of patient information such as tracing reports and continuous training sessions by the team-based learning method. In this study, we evaluated the clinical effectiveness of this collaboration system in patients treated with oral anti-cancer drugs as adjuvant chemotherapy for gastrointestinal cancers. This retrospective study involved outpatients who started adjuvant chemotherapy including tegafur-gimeracil-oteracil potassium or capecitabine during the pre-collaboration period (from January to September 2016) and the post-collaboration period (from August 2018 to April 2019) of 9 months, respectively. Forty-five and 65 outpatients visited our hospital in the pre-collaboration and post-collaboration periods, respectively. The rate of treatment discontinuation due to side effects within 3 months of the start of treatment was significantly lower during the post-collaboration period than the pre-collaboration period (2 patients (3.1％) versus 7 patients (15.6％), P = 0.03). There were no significant differences between pre- and post-collaboration periods in the rates of emergency consultation and emergency hospitalization for 3 months after the start of treatment (emergency consultation: 9 patients (20.0％) versus 12 patients (18.5％), P = 1.00; emergency hospitalization: 6 patients (13.3％) versus 4 patients (6.2％), P = 0.31). These results suggest that this collaboration system could contribute to the reduction of treatment discontinuation due to the side effects of adjuvant chemotherapy for gastrointestinal cancers.
